ACE2 inhibition leads to pulmonary fibrosis (WP5035)

Homo sapiens

Open in new tab
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
This AOP outlines how ACE-2 plays a detrimental role in causing fibrotic damage to the lung by influencing various factors such as fibrogenic components, proinflammatory cytokines, and a lack of oxygen. When the activity of ACE2 is suppressed, the conversion of Ang II into Ang-(1-7) is not properly facilitated. Consequently, the levels of proinflammatory Ang II rise, while the levels of anti-inflammatory Ang-(1-7) decrease. Notably, ACE2 inhibition has been observed to raise the levels of Ang II peptides, which are a ligand for the type 1 angiotensin receptor (AT1R). This phenomenon is considered a significant risk factor for lung fibrosis, vasoconstriction, endothelial dysfunction, and cell death.

Authors

Marvin Martens , Finterly Hu , and Alex Pico

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Adverse Outcome Pathways COVID-19

Annotations

Cell Type Ontology

fibroblast

Disease Ontology

COVID-19 pulmonary fibrosis

Pathway Ontology

angiotensin II signaling pathway via AT1 receptor

Participants

Label Type Compact URI Comment

References

  1. Understanding COVID-19 through adverse outcome pathways - 2nd CIAO AOP Design Workshop. Wittwehr C, Amorim MJ, Clerbaux LA, Krebs C, Landesmann B, Macmillan DS, et al. ALTEX. 2021;38(2):351–7. PubMed Europe PMC Scholia
  2. Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework. Nymark P, Sachana M, Leite SB, Sund J, Krebs CE, Sullivan K, et al. Front Public Health. 2021 May 19;9:638605. PubMed Europe PMC Scholia
  3. COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop. Clerbaux LA, Amigó N, Amorim MJ, Bal-Price A, Batista Leite S, Beronius A, et al. ALTEX. 2022;39(2):322–35. PubMed Europe PMC Scholia